黄艳丽 钱丽洁 陈凤娟 徐清 王雄

[摘要]目的：探讨点阵射频联合重组牛碱性成纤维细胞生长因子外用凝胶治疗痤疮凹陷性瘢痕的临床效果及安全性。方法：30例凹陷性痤疮瘢痕患者，采取点阵射频联合重组牛碱性成纤维细胞生长因子外用凝胶治疗，每月治疗1次，连续治疗3次，对比患者治疗前后ECCA评分及不良反应发生等情况，评价患者痤疮瘢痕改善情况。结果：治疗后ECCA权重评分明显低于治疗前，差异有统计学意义（P<0.01），无严重不良反应。结论：点阵射频联合重组牛碱性成纤维细胞生长因子外用凝胶治疗痤疮凹陷性瘢痕安全有效。

[关键词]点阵射频;重组牛碱性成纤维细胞生长因子外用凝胶;痤疮瘢痕;不良反应

[中图分类号]R619+.6    [文献标志码]A    [文章编号]1008-6455（2021）05-0094-03

Clinical Observation on the Treatment of Atrophic Acne Scar with Dot Matrix Radiofrequency Combined and Recombinant Bovine Basic Fibroblast Growth Factor

HUANG Yan-li1 ，QIAN Li-jie1，CHEN Feng-juan1，XU Qing2，WANG Xiong1

（1.Department of Dermatology，Shanghai Jiao Tong University Affiliated Sixth People's Hospital， Shanghai 200233，China;

2. Department of Cosmetology， Hubei Hospital of Traditional Chinese Medicine，Wuhan 430061， Hubei，China）

Abstract：Objective To explore the clinical efficacy and safety of dot matrix radiofrequency combined with recombinant bovine basic fibroblast growth factor （bFGF） gel on the treatment of atrophic acne scars. Methods 30 patients with atrophic acne scars were treated with dot matrix radiofrequency combined with recombinant bovine basic fibroblast growth factor gel once a month. After 3 consecutive t treatments， the efficacy was evaluated by comparing the ECCA weight score ，and observed adverse reactions. Results The ECCA weight score after treatment was significantly lower， with no serious adverse reactions. Conclusion Dot matrix radiofrequency combined with recombinant bovine basic fibroblast growth factor is safe and effective in the treatment of atrophic acne scars.

Key words：dot matrix radiofrequency;recombinant bovine basic fibroblast growth factor gel; atrophic acne scars; adverse reactions

痤疮凹陷性瘢痕是痤疮的严重后遗症，也是临床治疗的难点，对患者外貌和生活质量造成负面影响[1]。目前，对于痤疮凹陷性瘢痕的治疗方法主要有化学剥脱、射频、磨削、剥脱性点阵激光、非剥脱性点阵激光、离子束、微针、组织填充及手术切除等，治疗周期长，各个治疗方案临床效果不一，也可能出現各种不良反应[2]，比如：炎症后色素沉着、面部持久红斑及感染等。笔者科室采用点阵射频联合重组牛碱性成纤维细胞生长因子外用凝胶（Basic fibroblast growth factor，bFGF）治疗痤疮凹陷性瘢痕，取得了较满意的临床效果，现报道如下。

1  资料和方法

1.1 一般资料：收集2018年5月-2020年5月笔者医院门诊接诊的30例痤疮凹陷性瘢痕患者为研究对象，其中男23例，女7例，年龄18～35岁，平均（25.74±4.83）年，凹陷性痤疮瘢痕病程1～5年，平均（1.79±1.35）年。纳入标准：①年龄≥18岁;②痤疮凹陷性瘢痕稳定1年以上，瘢痕主要为冰锥型、箱车型以及碾压型;③治疗前与患者签订知情同意书，本研究治疗方案符合医学伦理委员会的要求。……